Betfarma

Dopamine agonist (PPID (Cushings))

BET Cabergoline LA 5 mg/ml Injectable IM

A dopamine agonist, like pergolide mesylate, used for the treatment of Pituitary Pars Intermedia Dysfunction (PPID), previously known as Equine Cushing’s Syndrome.

In a long-acting (LA) BET-BioRelease formulation, it is administered IM every 15 days.

A possible adverse effect of dopamine agonists, such as pergolide and cabergoline, is a temporary decrease in appetite following administration, without resulting in weight loss.

Hebert, R.C. et al. (2013)
Velencia, N.A. et al. (2014)
Bracken, A. et al. (2024)
Hess, H. et al. (2025)
Bracken, A. et al. (2026)

Additional veterinary applications include:

treatment of canine pseudocyesis;
inhibition of lactation in dogs, cats, and horses;
induction of estrus in dogs and cats;
treatment of pituitary-dependent hypercortisolism in dogs;
treatment of feline acromegaly;
improvement of insulin resistance in cats with Diabetes Mellitus.

This formulation has been used by veterinarians in the United States since 2003.

For more information, please contact us via WhatsApp at +55 (21) 97101-9404
or by email at contato@betfarmacia.com.br.
Soon, you’ll be able to access scientific research directly on the B.E.T. Farma website, in the exclusive area for veterinary professionals.

Estrogens

BET 17 Beta-Estradiol LA 10 mg/ml and 50 mg/ml Injectable IM

Bioidentical estrogen hormone.

10 mg/ml concentration:

A single dose may be used in the preparation of recipient mares for equine embryo transfer programs.

It may also be used in the protocol treatment of ascending placentitis in mares.

50 mg/ml concentration:

A high-concentration 17β-estradiol formulation designed to achieve elevated estrogen levels within 48 hours.

Its rapid onset of action, facilitated by the BET-BioRelease vehicle, combined with its high concentration per ml, facilitates administration and its use in treatment protocols for ascending placentitis in mares.

It may also be used for the preparation of recipient mares in equine embryo transfer programs.

Pinto, C. & Burn, P.J. (2004)
Douglas, R.H. (2004)
Curcio, B.R. et al. (2016)

This formulation has been used by veterinarians in the United States since 2002.

Reproductive Glycoproteins and Peptides

BET Deslorelin LA 1.5 mg/ml Injectable IM

Deslorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH).

Veterinary applications include:

ovulation induction in mares;
reversible reproductive suppression in dogs and cats;
management of hormone-related behavioral disorders in dogs and cats;
management of benign prostatic hyperplasia (BPH) in dogs.

Fleury, P.D.C. et al. (2004)
M. Kölling and W.R. Allen (2005)
Lanna, L.L. et al. (2010)
Finan, S.A., Lamkinb, E.L. & McKinnon, A.O. (2016)

This formulation has been used by veterinarians in the United States since 2002.

BET Deslorelin (1.5 mg/ml) + hCG (1,500 IU/ml) LA Injectable IM

A combination of a GnRH analogue and Human Chorionic Gonadotropin (hCG).

Developed to induce ovulation in mares, with the potential to improve synchronization of ovulation.

Sanches, F.A. et al. (2025)
Jacob, J.C.F. et al. (2026)

Ready-to-use formulation; it is not lyophilized, no reconstitution required.

Stability testing has demonstrated that our exclusive BET-BioRelease vehicle maintains hCG stability, allowing the formulation to be stored at room temperature up to 40°C.

BET hCG LA 1,000 IU/ml Injectable IM

Human Chorionic Gonadotropin (hCG).

Veterinary applications include:

induction of ovulation in mares;
assisting in the diagnosis of cryptorchidism in dogs;
induction or synchronization of ovulation and treatment of follicular cysts in dogs.

Sanches, F.A. et al (2025)

Ready-to-use formulation; it is not lyophilized, no reconstitution required.

Stability testing has demonstrated that our exclusive BET-BioRelease vehicle maintains hCG stability, allowing the formulation to be stored at room temperature up to 40°C.

Progestins

BET Altrenogest LA 150 mg/ml Injectable IM

Synthetic progesterone in a long-acting (LA) BET-BioRelease formulation.

Veterinary applications include:

estrus suppression in mares: IM administration every 12 or 15 days.
pregnancy maintenance in mares: IM administration every 7 or 12 days.

Morrow, C.M. & Burns, P.J. (2007)

This formulation has been used by veterinarians in the United States since 2005.

BET Progesterone LA 300 mg/ml Injectable IM

Bioidentical progesterone in a long-acting (LA) BET-BioRelease formulation.

A pioneering formulation in veterinary medicine, developed using the BET-BioRelease delivery system to mimic the phisiological release of progesterone from the corpus luteum (CL), promoting the return to estrus approximately 14 days after administration.

Veterinary applications include:

a single dose for the preparation of recipient mares in equine embryo transfer programs, replacing the vaginal implant;
maintenance of pregnancy in anestrous mares, administered IM every 7 days;
maintenance of pregnancy in cyclic mares, administered IM every 14 days, if serum progesterone levels are above 2 ng/ml;
maintenance of pregnancy in female dogs with luteal insufficiency.

Bringel, B. et al. (2003)
Bringel, B. et al. (2004)
Burn, P. et al. (2007)

This formulation has been used by veterinarians in the United States since 2002.

Medications

Dopamine agonist (PPID (Cushings))

BET Cabergoline LA 5 mg/ml Injectable IM

Estrogens

BET 17 Beta-Estradiol LA 10 mg/ml and 50 mg/ml Injectable IM

Reproductive Glycoproteins and Peptides

BET Deslorelin LA 1.5 mg/ml Injectable IM

BET Deslorelin (1.5 mg/ml) + hCG (1,500 IU/ml) LA Injectable IM

BET hCG LA 1,000 IU/ml Injectable IM

Progestins

BET Altrenogest LA 150 mg/ml Injectable IM

BET Progesterone LA 300 mg/ml Injectable IM

Follow us on social media and keep up with all the news